Alaunos Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on July 3, 2025. Stockholders approved an amendment to increase the number of authorized shares of common stock from 5,000,000 to 50,000,000. An amendment to the 2020 Equity Incentive Plan to increase the number of shares issuable under the plan from 130,745 to 1,130,745 was also approved. Additionally, the proposal to adjourn the meeting if necessary was approved. All three nominated directors were elected.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.